Measuring quality of life in multiple sclerosis patients with urinary disorders using the qualiveen questionnaire

Archives of Physical Medicine and Rehabilitation

Volumn 85, Issue 8, 2004, Pages 1317-1323

  Bonniaud, Véronique ^a,b,d,e   Parratte, Bernard ^b   Amarenco, Gérard ^c   Jackowski, Dianne ^d   Didier, Jean Pierre ^a   Guyatt, Gordon ^d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d MCMASTER UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Bladder, neurogenic; Multiple sclerosis; Quality of life; Rehabilitation

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; BLADDER FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; FEMALE; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; PREDICTION; QUALITY OF LIFE; QUESTIONNAIRE; SPINAL CORD INJURY; URINARY TRACT DISEASE; VALIDATION PROCESS;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; DISCRIMINANT ANALYSIS; FEAR; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SELF CARE; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; URINATION DISORDERS; URODYNAMICS;

EID: 3543091005     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2003.09.029     Document Type: Article

References (53)

1. Rothwell P.M., McDowell Z., Wong C.K., Dorman P.J. Doctors and patients don't agree cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 314:1997;1580-1583
2. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of life. Can J Neurol Sci. 25:1998;31-38
3. Nortvedt M.W., Riise T., Myhr K.M., Nyland H.I. Quality of life in multiple sclerosis measuring the disease effects more broadly. Neurology. 53:1999;1098-1103
4. Lankhorst G.J., Jelles F., Smits R.C., et al. Quality of life in multiple sclerosis the disability and impact profile (DIP). J Neurol. 243:1996;469-474
5. Cost of Multiple Sclerosis Study Group, Murphy N., Confavreux C., Haas J., et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. J Neurol Neurosurg Psychiatry. 65:1998;460-466
6. Freeman J.A., Thompson A.J., Fitzpatrick R., et al. Interferon-beta1b in the treatment of secondary progressive MS impact on quality of life. Neurology. 57:2001;1870-1875
7. Lintern T.C., Beaumont J.G., Kenealy P.M., Murrell R.C. Quality of Life (QOL) in severely disabled multiple sclerosis patients comparison of three QoL measures using multidimensional scaling. Qual Life Res. 10:2001;371-378
8. Nortvedt M.W., Riise T., Myhr K.M., Nyland H.I. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 38:2000;1022-1028
9. Brunet D.G., Hopman W.M., Singer M.A., Edgar C.M., MacKenzie T.A. Measurement of health-related quality of life in multiple sclerosis patients. Can J Neurol Sci. 23:1996;99-103
10. Pfennings L., Cohen L., Miller D., et al. Using the Short Form-36 with multiple sclerosis patients in five countries a cross-cultural comparison. Psychol Rep. 85:1999;19-31
11. Arnoldus J.H., Killestein J., Pfennings L.E., Jelles B., Uitdehaag B.M., Polman C.H. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler. 6:2000;338-342
12. Miller D.M., Rudick R.A., Cutter G., Baier M., Fischer J.S. Clinical significance of the multiple sclerosis functional composite relationship to patient-reported quality of life. Arch Neurol. 57:2000;1319-1324
13. Wiebe S., Guyatt G., Weaver B., Matijevic S., Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 56:2003;52-60
14. Vickrey B.G., Hays R.D., Harooni R., Myers L.W., Ellison G.W. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 4:1995;187-206
15. Cella D.F., Dineen K., Arnason B., et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 47:1996;129-139
16. Fischer J.S., LaRocca N.G., Miller D.M., Ritvo P.G., Andrews H., Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler. 5:1999;251-259
17. Pfennings L.E., Van der Ploeg H.M., Cohen L., et al. A health-related quality of life questionnaire for multiple sclerosis patients. Acta Neurol Scand. 100:1999;148-155
18. Ford H.L., Gerry E., Tennant A., Whalley D., Haigh R., Johnson M.H. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil. 15:2001;247-258
19. Gold S.M., Heesen C., Schulz H., et al. Disease specific quality of life instruments in multiple sclerosis validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler. 7:2001;119-130
20. Hobart J., Lamping D., Fitzpatrick R., Riazi A., Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29) a new patient-based outcome measure. Brain. 124:(Pt 5):2001;962-973
21. Sliwa J.A., Bell H.K., Mason K.D., Gore R.M., Nanninga J., Cohen B. Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms. Arch Phys Med Rehabil. 77:1996;247-251
22. Perrigot M., Richard F., Veaux-Renault V., Chatelain C., Küss R. Les troubles vésicosphinctériens dans la sclérose en plaques sémiologie et évolution. A propos de 100 cas. Ann Urol. 3:1982;147-150
23. Parratte B., Bonniaud V., Vuillier F., Tatu L., Rumbach L., Monnier G. [Urinary disorders, functional exploration of the urinary tract, and multiple sclerosis] [French]. Rev Neurol (Paris). 158:(10 Pt 1):2002;1019-1024
24. Chancellor M.B., Blaivas J.G. Urological and sexual problems in multiple sclerosis. Clin Neurosci. 2:1994;189-195
25. Nortvedt M.W., Riise T., Myhr K.M., Landtblom A.M., Bakke A., Nyland H.I. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler. 7:2001;231-235
26. Amarenco G., Kerdraon J., Denys P. [Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases] [French]. Rev Neurol. 151:1995;722-730
27. Gallien P., Robineau S., Nicolas B., Le Bot M.P., Brissot R., Verin M. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis a study of 149 cases. Arch Phys Med Rehabil. 79:1998;255-257
28. Barry M.J., Fowler F.J. Jr, O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., Mebust W.K. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care. 33:(Suppl 4):1995;AS145-AS155
29. Bosch J.L., Hop W.C., Kirkels W.J., Schroder F.H. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol. 75:1995;622-630
30. Donovan J.L., Abrams P., Peters T.J., et al. The ICS-"BPH" Study the psychometric validity and reliability of the ICS male questionnaire. Br J Urol. 77:1996;554-562
31. Epstein R.S., Deverka P.A., Chute C.G., et al. Urinary symptom and quality of life questions indicative of obstructive benign prostatic hyperplasia. Results of a pilot study. Urology. 38:(Suppl 1):1991;20-26
32. Lukacs B., McCarthy C., Grange J.C. Long-term quality of life in patients with benign prostatic hypertrophy preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice. Eur Urol. 24:(Suppl 1):1993;34-40
33. Black N., Griffiths J., Pope C. Development of a symptom severity index and a symptom impact index for stress incontinence in women. Neurourol Urodyn. 15:1996;630-640
34. Jackson S., Donovan J., Brookes S., Eckford S., Swithinbank L., Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire development and psychometric testing. Br J Urol. 77:1996;805-812
35. Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 104:1997;1374-1379
36. Lee P.S., Reid D.W., Saltmarche A., Linton L. Measuring the psychosocial impact of urinary incontinence the York Incontinence Perceptions Scale (YIPS). J Am Geriatr Soc. 43:1995;1275-1278
37. Continence Program in Women (CPW) Research Group, Shumaker S.A., Wyman J.F., Uebersax J.S., McClish D., Fantl J.A. Health-related quality of life measures for women with urinary incontinence the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res. 3:1994;291-306
38. Wagner T.H., Patrick D.L., Bavendam T.G., Martin M.L., Buesching D.P. Quality of life of persons with urinary incontinence development of a new measure. Urology. 47:1996;67-71. discussion 71-2
39. DuBeau C.E., Kiely D.K., Resnick N.M. Quality of life impact of urge incontinence in older persons a new measure and conceptual structure. J Am Geriatr Soc. 47:1999;989-994
40. Lubeck D.P., Prebil L.A., Peeples P., Brown J.S. A health related quality of life measure for use in patients with urge urinary incontinence a validation study. Qual Life Res. 8:1999;337-344
41. Coyne K., Revicki D., Hunt T., et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire the OAB-q. Qual Life Res. 11:2002;563-574
42. Guyatt G.H., Feeny D.H., Patrick D.L. Measuring health-related quality of life. Ann Intern Med. 118:1993;622-629
43. Costa P., Perrouin-Verbe B., Colvez A., et al. Quality of life in spinal cord injury patients with urinary difficulties. Development of validation of qualiveen. Euro Urol. 39:2001;107-113
44. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis guidelines for research protocols. Ann Neurol. 13:1983;227-231
45. Kurtzke J.F. Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? Neurol Sci. 21:2000;339-341
46. Sharrack B., Hughes R.A., Soudain S., Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 122:(Pt 1):1999;141-159
47. Hobart J., Freeman J., Thompson A. Kurtzke scales revisited the application of psychometric methods to clinical intuition. Brain. 123:(Pt 5):2000;1027-1040
48. Vernay D., Gerbaud L., Biolay S., Coste J., Debourse J., Aufauvre D., et al. [Quality of life and multiple sclerosis validation of the French version of the self-questionnaire (SEP-59)]. [French] Rev Neurol (Paris). 156:2000;247-263
49. Guyatt G.H., Berman L.B., Townsend M., Pugsley S.O., Chambers L.W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 42:1987;773-778
50. Cohen J. Weighted kappa nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 70:1968;213-220
51. Guyatt G.H., Kirshner B., Jaeschke R. Measuring health status what are the necessary measurement properties? J Clin Epidemiol. 45:1992;1341-1345
52. Guyatt G.H., Deyo R.A., Charlson M., Levine M.N., Mitchell A. Responsiveness and validity in health status measurement a clarification. J Clin Epidemiol. 42:1989;403-408
53. Guyatt G., Walter S., Norman G. Measuring change over time assessing the usefulness of evaluative instruments. J Chronic Dis. 40:1987;171-178